Owen B. Wallace - 12 Apr 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Scientific Officer
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Issuer symbol
GLUE
Transactions as of
12 Apr 2021
Net transactions value
$0
Form type
4
Filing time
25 Jun 2021, 17:00:46 UTC
Next filing
23 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +387,069 $0.000000 387,069 12 Apr 2021 Common Stock 387,069 $6.14 Direct F1, F2, F3
transaction GLUE Stock Option (Right to Buy) Award $0 +113,298 $0.000000 113,298 23 Jun 2021 Common Stock 113,298 $19.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
F2 This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F3 25% of this option shall vest and become exercisable on February 8, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4 25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.